跳至主要内容
临床试验/CTRI/2021/06/034254
CTRI/2021/06/034254已完成未知

Randomized controlled clinical trial to assess the efficacy and safety of APMV2020 in mild symptomatic subjects of COVID 19 - Nil

Meyer Organics Pvt Ltd0 个研究点目标入组 320 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
320

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age -18- 60 years (Both sex)
  • 2.Confirmed COVID 19 patient with positive RT-PCR
  • 3.Mild symptomatic patients having no signs of severe disease (NEWS score ââ?°Â¤6)
  • 4.Home/ institutional quarantined subjects with no necessity of dedicated hospital admission at the time of screening
  • 5.Subject willing to provide consent and follow up for study duration

排除标准

  • 1.Patients with autoimmune disease or self-reports HIV or syphilis infection
  • 2.Subject suffering from disorders where Aspirin is contraindicated and/or as per the discretion of investigator
  • 3.Proves to be unfit for the study as per the investigatorââ?¬•s discretion
  • 4.Pregnant or lactating women
  • 5.Requiring hospital admission at screening
  • 6.Any other comorbidity which is critical stage at screening which in investigator discretion finds subject not suitable for the trial participation

研究者

发起方
Meyer Organics Pvt Ltd

相似试验